Elephas, a private company developing an oncology imaging diagnostics platform, has raised $55 million in Series C funding. The funding round was led by Venture Investors Health Fund and the State of Wisconsin Investment Board, with participation from other investors including Northpond Ventures and ARCH Ventures. Elephas aims to use the funding to advance its live tumor imaging diagnostic platform, which uses metabolic imaging and live patient biopsies to predict response to immunotherapy. The company is conducting observational clinical trials to demonstrate the correlation between a patient’s clinical response to immunotherapy and data obtained from the Elephas platform.
Elephas Raises $55M: Fueling Future Growth with Series C

Latest from Blog

VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in

VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity

Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.

Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI

Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in